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http://dx.doi.org/10.1016/j.jmii.2013Background: Candidemia remains a major cause of morbidity and mortality in the health care
setting, and the epidemiology of Candida infection is changing.
Methods: Clinical and laboratory data from patients with candidemia were collected retro-
spectively at a tertiary medical center in Taiwan from July 1, 2009 to June 30, 2012 (a 36-
month period). Demographics, clinical characteristics, and drug susceptibility of the invading
Candida species of patients at the onset of candidemia were analyzed and compared with pre-
vious study from January 1, 2001 to June 30, 2003 (a 30-month period).
Results: A total of 209 episodes of candidemia in 205 patients were identified in this study
period. When compared with the previous study period, more patients were admitted for med-
ical conditions at percentages ranging from 49.5% to 69.8%; the incidence rate of health care-
associated candidemia increased from 0.76 to 1.14 per 1000 discharges; the proportion of
Candida albicans in patients with candidemia decreased from 64.8% to 43.6% whereas
the proportion of Candida glabrata increased greatly from 1.1% to 21.6% and the proportions
of Candida tropicalis and Candida parapsilosis were slightly elevated (19.8e22.0% and
2.2e7.3%, respectively). All of the C. albicans isolates remained susceptible to fluconazole,
whereas 66.7% of C. glabrata isolates were dose-dependent susceptible, and 4.4% of C. glab-
rata isolates and 11.6% C. tropicalis isolates were resistant. There was one C. glabrata and one
Candida guilliermondii resistant to echinocandin. The predictors for 30-day mortality included
the high Acute Physiology and Chronic Health Evaluation II (APACHE II) score, use of parenteral
nutrition, underlying malignancy, liver cirrhosis, and neutropenia whereas candidemia by
C. parapsilosis or C. glabrata is a favorable predictor when compared with C. albicans.Infectious Diseases, Department of Internal Medicine, Changhua Christian Hospital, 135 Nanhsiao
(C.-Y. Chang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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Epidemiology of candidemia 307Conclusion: The distribution of Candida species in candidemia was changed. Although C. albi-
cans remained the major species, the isolation of non-C. albicans spp., especially C. glabrata,
increased. Patients with candidemia still had high mortalities due to severity of illness and un-
derlying conditions.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Invasive candidiasis has been one of the important issues in
clinical settings and has been a leading cause of health
care-associated infections (HAIs), resulting in increased
length and cost of hospitalizations as well as morbidities/
mortalities of patients.1 In Taiwan, candidemia is the
second most common cause of health care-associated
bloodstream infections (HA-BSIs), ranking only after
bacteremia by Staphylococcus species and followed by
Acinetobacter baumannii and Escherichia coli bacteremia.
Furthermore, although health care-associated bloodstream
infections by pathogens such as S. aureus and Pseudomonas
aeruginosa are decreasing, the incidence of candidemia is
increasing.2e4 The reasons for increased candidal infections
are thought to be due to the use of broad-spectrum anti-
biotics and immunosuppressants such as steroids, prolonged
hospital and intensive care unit (ICU) stay, increased inva-
sive procedures in medical practices, and more compli-
cated underlying diseases such as malignancies, as well as
prolonged survival of patients in the modern health care
system.5e7 The epidemiology of candidemia, however,
varies among different geographic areas and time periods.8
Therefore, the knowledge of the local epidemiology of
candidal infections is important to offer the sound man-
agement of invasive candidiasis.9 In this study, we retro-
spectively reviewed the cases of candidemia from July 1,
2009 to June 30, 2012 in Changhua Christian Hospital (CCH),
performed the antifungal susceptibility testing for the
available clinical isolates, and compared the results with
that of our previous study10 to clarify the changing epide-
miology of candidemia.Materials and methods
Patients and setting
All the patients were included if they were older than 16
years with at least one blood culture positive for Candida
species from July 1, 2009 to June 30, 2012 in Changhua
Christian Hospital, a 1700-bed tertiary hospital providing
primary and tertiary patient care in middle Taiwan with 166
ICU beds for medical and surgical adult patients and pedi-
atric patients.
Data collected from the medical records of the patients
included demographic characteristics, underlying diseases
(e.g., malignancy, diabetes mellitus, renal failure, liver
cirrhosis), other associated conditions (e.g., concurrent
bacteremia, Candida colonization, neutropenia, broad-
spectrum antibiotics use, central venous catheterization,
shock, parenteral nutrition, abdominal surgery, and steroiduse), Acute Physiology and Chronic Health Evaluation II
(APACHE II) scores, and outcome.
Definition
One episode of candidemia was defined by the isolation of
Candida species from one or more blood cultures in a pa-
tient. If more than one blood culture was positive, a new
episode was defined if more than 30 days had elapsed since
the previous positive blood culture unless a persistent focus
was identified. Episodes of candidemia were categorized as
community acquired or healthcare associated following
the definition of the Centers for Disease Control and
Prevention.11,12 Except for impaired renal function, which
was determined by estimated glomerular filtration
rate < 30 mL/min/1.73 m2 or creatinine more than 2 mg/dL
on presentation, the classification of patients with under-
lying conditions including malignancy, diabetes mellitus,
and liver cirrhosis were determined by clear documentation
of the diagnoses and/or associated treatment in medical
records. Other definitions of terms used in this study are in
concordance with our previous study10 and are described
briefly: Candida colonization is defined as the presence of
the same Candida species in both non-sterile (obtained
from urine, stool, and pus from a surgical wound) and
sterile (such as a central venous catheter tip) specimens
within the 14 days before and after the onset candidemia.
Neutropenia is defined as absolute neutrophil count < 500
cells/mm3. Central venous catheterization is the presence
of a central venous catheter within 2 weeks of the onset of
candidemia. Shock is defined as a decrease in systolic blood
pressure to a level of less than 90 mmHg or a decrease of at
least 40 mmHg from baseline blood pressure despite
adequate fluid resuscitation or the use of vasopressors.
Corticosteroid treatment is defined as receiving cortico-
steroids equivalent to prednisolone to at least 20 mg/day
more than 7 days within 4 weeks of the onset of candide-
mia. Abdominal surgery is defined as an abdominal surgical
procedure that was performed within 1 month of the onset
of candidemia. Severity of illness was assessed by APACHE II
scores. Receipt of parenteral nutrition is defined as the
administration of lipid emulsion nutrition via peripheral or
central veins for more than 3 days within 1 week prior to
candidemia episode. Thirty-day crude mortality was used
for primary outcome analysis.
Isolation, identification, and antifungal
susceptibility testing of Candida isolates
There was no difference in the culture system and identi-
fication system between the two study periods. The blood
308 I.-M. Hii et al.specimens were cultured in the BD BACTEC FX (Becton
Dickinson, Sparks, MD, USA, www.bd.com) blood culture
system, which is fully automated for microorganism growth
detection. A yeast-like microorganism was detected by
microscopic inspection after Gram staining and the growth
characteristics were seen on agar plates. Further identifi-
cation was performed using the API Candida Manufacturer:
BioMerieux, Marcy L-Etoile, France yeast identification
system. All blood isolates were stored at e80C in the
Thermo Scientific Forma (Thermo Fisher Scientific, Wal-
tham, Massachusetts, USA, www.thermofisher.com) 900
series 955 model. For drug susceptibility testing, all avail-
able stored isolates were thawed and inoculated to Sabo-
uraud dextrose agars (SDA) and incubated in an incubator at
35C for 24e25 hours. The procedures were done according
to manufacturer’s protocol of Sensitire YeastOne (TREK
Diagnostic Systems, Units 17-19 Birches Industrial Estate,
East Grinstead,West Sussex. RH19 1XZ, UK).13 Briefly, we
placed the yeast colonies from the SDA plates into test
tubes containing 10 mL normal saline, and vortexed and
adjusted the turbidity of the suspensions to 0.5 Mcfarland.
The suspensions were then placed into the panel wells and
incubated in a 35C incubator for 24e25 hours. A control
well without an antifungal agent was used for ensuring the
quality of growth and purity that the suspension from the
well after incubation was subcultured onto another SDA
plate to make sure the growth of 10e80 pure colonies for
each corresponding candidal isolate. The panel wells were
read and interpreted automatically using a Vizion instru-
ment (Thermo Scientific Sensititre Vizion Digital MIC
Viewing System, Manufacturer: Thermo Fisher Scientific,
Waltham, Massachusetts, USA, www.thermofisher.com).
Statistical analysis
Univariate analyses were performed to examine the differ-
ences of characteristics of patients between two study pe-
riods and to identify possible risk factors associated with 30-
day mortality of patients. For categorical measures, the
Pearson chi-square or Fisher exact test was carried out as
appropriate. For continuousmeasures, the Student t test was
used. Results with p < 0.05 were considered statistically sig-
nificant. Multivariate analyses using stepwise logistic regres-
sion were performed to identify independent factors
associatedwith 30-daymortality in patientswith candidemia.
Predictors that improved the multiple logistic regression
model with p < 0.05 were allowed to enter into the model.
Results
Characteristics of patients
During the study period, 217 cases of candidemia were
identified from the database of the microbiological labo-
ratory in our institute and 12 pediatric cases (age 16 years
or younger) were excluded from the study. A total of 218
Candida isolates from 209 candidemia episodes in 205 pa-
tients were included for analysis. Among these patients,
four patients had two candidemia episodes, including one
having the same species (C. glabrata) in two episodes and
three having different species for each episode (C.albicans/C. tropicalis, C. glabrata/C. tropicalis and C.
albicans/Candida spp. in each patient) and 201 patients
had one candidemia episode, including nine patients having
two kinds of candidal species in the same episode (C.
albicans/C. glabrata in four patients, C. glabrata/C. tro-
picalis in two, and C. albicans/C. tropicalis, C. para-
psilosis/C. tropicalis and C. famata/Candida spp. both in
one patient each). Among 209 candidemic episodes, 195
(93.3%) were healthcare associated. The incidence of
healthcare-associated candidemia was estimated to be
1.14 episodes per 1000 discharges in the current study
period, significantly higher than that in the previous study
(0.76/1000 discharges, p < 0.002). The demographic and
clinical characteristics of patients were summarized and
compared with that of a previous study as shown in Table 1.
When compared with the previous study, more patients
(69.8%) were admitted to the medical units while the pro-
portion of admissions to the surgical intensive care units
(SICU) was significantly decreased from 36.3% to 10.0%
(p < 0.001). There was an increasing trend in the propor-
tion of patients with malignancy although not statistically
significant (38.5% vs. 46.9%, p Z 0.177). For known factors
predisposing to candidemia, the percentage of patients
with recent abdominal surgery was significantly decreased
from 39.6% to 21.5% (pZ 0.001). A decreased proportion of
patents with parenteral nutrition from 40.7% to 32.5% and
increased proportion of patients with neutropenia from
6.6% to 11% were noted, but these were not statistically
significant (p Z 0.175 and 0.235, respectively). The distri-
bution of Candida species in candidemia was different be-
tween the two study periods. Although C. albicans
remained the most common isolated candidal species, the
proportion declined from 64.8% to 43.6%. This was largely
due to the significantly increased isolation of C. glabrata
(1.1e21.6%), which had become the third most common
isolated candidal species in the current study. The fre-
quencies of isolation for C. tropicalis and C. parapsilosis
were also slightly elevated (19.8% to 22.0% and 2.2% to
7.3%, respectively) and partially responsible for the
increased proportion of non-C. albicans candidemia.
The characteristics of patients with pure candidemia of
the four major Candida species, e.g., C. albicans, C. tro-
picalis, C. glabrata, and C. parapsilosis in their episodes
were compared to identify host factors associated with
specific Candida species in Table 2. We revealed that pa-
tients with C. glabrata candidemia were more likely to be
female (58.5%) and older (mean age  standard deviation
[SD] Z 70  16); patients with C. tropicalis candidemia
were less likely to have diabetes mellitus (20.5%) and more
likely to be predisposed to neutropenia (27.3%); patients
with C. parapsilosis candidemia were younger (mean
age  SDZ 60  15), and less likely to have colonization of
the same species at sites other than bloodstream (13.3%);
and patients with C. albicans or C. glabrata were likely to
present with impaired renal function. Higher proportion of
patients with C. tropicalis or C. glabrata were exposed to
fluconazole before onset of candidemia (22.7% and 19.5%,
respectively) but this is not statistically significant
(p Z 0.210). Patients with C. tropicalis had the worst
outcomes with 65.9% of 30-day mortality whereas C. par-
apsilosis was associated with the lowest mortality rate
(20.0% of 30-day mortality).
Table 1 Comparison of the characteristics of patients with candidemia in 2001e2003 versus 2009e2012
Study period p
2001/1e2003/6 (N Z 91) 2009/7e2012/6 (N Z 209)
Sex M 51 (56.0) 130 (62.2) 0.316
F 40 (44.0) 79 (37.8)
Age, y 68  11 (32e96) 66  15 (20e95) 0.875
Admitting ward type ER 0 (0) 1 (0.5) < 0.001
Medical ward 22 (24.2) 100 (47.8)
MICU 23 (25.3) 46 (22.0)
SICU 33 (36.3) 21 (10.0)
Surgical ward 13 (14.3) 41 (19.6)
APACHE II score 18  9 (0e38) 19  8 (0e42) 0.616
Time from admission to candidemia, d 19  16 (0e107) 16  18 (0e118) 0.021
Time from candidemia to antifungal therapy, d 2  3 (e19) 0  3 (e23) < 0.001
Length of hospital stay, d 39  31 (0e176) 37  37 (0e270) 0.153
Colonization with Candida speciesa 48/79 (60.8) 101/179 (56.4) 0.74
Concurrent bacteremia 21 (23.1) 71 (34.0) 0.06
30-d mortality 47 (51.6) 112 (53.6) 0.757
Underlying conditions
Malignancy 35 (38.5) 98 (46.9) 0.177
Diabetes mellitus 33 (36.3) 71 (34.0) 0.701
Impaired renal function 44 (48.4) 97 (46.4) 0.757
Cirrhosis 9 (9.9) 18 (8.6) 0.722
Predisposing factors
Broad spectrum antibiotic exposure 77 (84.6) 170 (81.3) 0.494
Central venous catheter 77 (84.6) 171 (81.8) 0.556
Parenteral nutrition 37 (40.7) 68 (32.5) 0.175
Recent abdominal surgery 36 (39.6) 45 (21.5) 0.001
Use of steroid 32 (35.2) 70 (33.5) 0.779
Neutropenia 6 (6.6) 23 (11.0) 0.235
Candida species
C. albicans 59 (64.8) 95 (43.6) < 0.001
C. tropicalis 18 (19.8) 48 (22.0)
C. glabrata 1 (1.1) 47 (21.6)
C. parapsilosis 2 (2.2) 16 (7.3)
C. krusei 1 (1.1) 3 (1.4)
C. guilliermondii 6 (6.6) 2 (0.9)
C. famata 1 (1.1) 1 (0.5)
C. membranifaciens 2 (2.2) 0 (0.0)
C. pelliculosa 0 (0.0) 1 (0.5)
C. sake 1 (1.1) 0 (0.0)
Undetermined Candida species 0 (0.0) 5 (2.3)
a n/n(%): no. of positivity for same Candida species/no. of microbiological investigation during candidemia episodes.
Data are n (%) or mean  standard deviation (minimumemaximum) unless otherwise indicated.
APACHE II Z Acute Physiology and Chronic Health Evaluation II; ER Z emergency room; MICU Z medical intensive care unit;
SICU Z surgical intensive care unit.
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A total of 205 clinical isolates from 190 patients from the
culture collections of the microbiological laboratory in our
institute were available for susceptibility testing. Three
isolates from three patients failed to produce results of
minimum inhibitory concentration for the drugs tested
drugs and finally a total of 202 candidal isolates from 187
patients were analyzed. The results are shown in Table 3.
Notably, no resistance to fluconazole was detected in 90 C.
albicans isolates. Two (4.4%) isolates of C. glabrata were
resistant to fluconazole and 30 (66.7%) isolates were dose-
dependent susceptible. There was no resistance tofluconazole in 18 C. tropicalis isolates in our previous study,
whereas five (11.6%) of C. tropicalis isolates showed resis-
tance to fluconazole in the current study. C. parapsilosis
isolates were well susceptible to fluconazole. All candidal
isolates except two (one C. glabrata and one C. guillier-
mondii) were susceptible to echinocandins. It was not
feasible to compare the susceptibility of Candida spp. to
echinocandins with that of our previous study in which the
susceptibility for echinocandins was not performed.
Table 4 showed that in the current study, female sex
and previous broad-spectrum antibiotic and fluconazole
exposure were significant factors associated with candide-
mia by fluconazole reduced-susceptible Candida strains in
Table 2 Comparisons of characteristics among the four most isolated Candida species
Variablesb C. albicans C. tropicalis C. glabrata C. parapsilosis p
n Z 90 n Z 44 n Z 41 n Z 15
Sex, male 62 (68.9) 28 (63.6) 17 (41.5) 10 (66.7) 0.026a
Age, y 66  14 62  19 70  16 60  15 0.050
APACHE II score 19  10 20  8 20  8 17  9 0.698
Underlying disease
Malignancy 40 (44.4) 22 (50) 19 (46.3) 10 (66.7) 0.446
DM 37 (41.1) 9 (20.5) 15 (36.6) 7 (46.7) 0.094
Impaired renal function 47 (52.2) 15 (34.1) 24 (58.5) 4 (26.7) 0.035a
Cirrhosis 11 (12.2) 4 (9.1) 1 (2.4) 0 (0) 0.172
Predisposing factor
Broad spectrum antibiotic exposure 71 (78.9) 39 (88.6) 36 (87.8) 9 (60) 0.055
CVC 75 (83.3) 36 (81.8) 30 (73.2) 13 (86.7) 0.515
Parenteral nutrition 28 (31.1) 14 (31.8) 13 (31.7) 6 (40) 0.924
Recent abdominal surgery 20 (22.2) 6 (13.6) 11 (26.8) 4 (26.7) 0.465
Use of steroid 30 (33.3) 16 (36.4) 14 (34.1) 3 (20) 0.707
Neutropenia 4 (4.4) 12 (27.3) 2 (4.9) 2 (13.3) < 0.001a
Associated conditions
Fluconazole exposure 10 (11.1) 10 (22.7) 8 (19.5) 1 (6.7) 0.210
Colonization investigation 79 (87.8) 37 (84.1) 35 (85.4) 12 (80) 0.846
Colonization with Candida species 47 (52.2) 20 (45.5) 21 (51.2) 2 (13.3) 0.043a
Concurrent bacteremia 36 (40) 11 (25) 11 (26.8) 5 (33.3) 0.265
30-d mortality 51 (56.7) 29 (65.9) 17 (41.5) 3 (20) 0.007a
a p < 0.05.
b Data are n (%) or mean  SD unless otherwise indicated.
APACHE IIZ Acute Physiology and Chronic Health Evaluation II; CVCZ central venous catheter; ERZ emergency room; MICUZmedical
intensive care unit; SICU Z surgical intensive care unit.
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are independent factors in multivariate analysis.
Treatment and outcome analysis
Of the 209 candidemia episodes, 39 (18.7%) were not
treated with antifungal agents. Most (28 of 39, 71.8%) were
due to deaths that occurred before the diagnoses of can-
didemia were made and effective treatment could be
commenced. In 170 treated episodes, the mean time from
candidemia episode to antifungal therapy was 0  3 days
and was significantly shorter than that of our previous study
(2  3 days, p < 0.001). However, the 30-day overall mor-
tality rate did not change (51.6% vs. 53.6%, p Z 0.757).
In identification of predictors for mortality in current
study, we revealed that APACHE II score, malignancy, liver
cirrhosis, use of parenteral nutrition, presence of central
venous catheter, use of steroid, neutropenia, and Candida
spp. were significantly associated with 30-day mortality in
univariate analysis. The effect of APACHE II score, malig-
nancy, liver cirrhosis, use of parenteral nutrition, neu-
tropenia, and Candida species on mortality was still present
in multivariate analysis. Patients with C. glabrata or C.
parapsilosis candidemia had more favorable outcomes then
those with C. albicans or C. tropicalis candidemia. The time
from onset of candidemia to effective antifungal therapy
and the susceptibility of Candida isolates did not show a
significant difference between survived and fatal episodes.
The results are shown in Table 5.Discussion
In Taiwan, the incidence of candidiasis in the health care
setting has been high and has increased in recent years.4
Our study revealed an increased trend of incidence of
health care-associated candidemia in our institute from
0.76/1000 discharges during 2001e2003 to 1.14/1000 dis-
charges during 2009e2012. Our candidemia incidence was
lower than that in the report by Chen et al,14 which
compared the characteristics of patients and the incidence
of candidemia between 2002 and 2010 in their hospital, and
although the incidence of candidemia did not increase
significantly (2.78 per 1000 admissions in 2002 and 2.88 per
1000 admissions in 2010, p Z 0.71), the incidence density
increased from 0.34 per 1000 patient-days in 2002 to 0.41
per 1000 patient-days in 2010 (p Z 0.04). The increased
incidence density of candidemia is thought to be associated
at least partly with the increase in the proportion of pa-
tients at a higher risk of candidemia, such as older age,
higher comorbidity, and more underlying disease/status,
including chronic pulmonary diseases, moderate to severe
renal diseases, leukemia, lymphoma, and gastrointestinal
malignancies. Although a hospital-wide analysis of patient
papulation is not performed in the current study, the
increased proportion of medical patients and decreased
proportion of patients with abdominal surgery among can-
didemia cases in our two study periods still indicated the
changing of the patient population and medical practices in
our institute.
Table 3 In vitro susceptibility test of Candida species of antifungal agents
Species (No. ) Antifungal agent Range MIC (mg/mL) % (%) R or
Non-S50% 90% S SDD
C. albicans (90) Amphotericin B 0.12 0.5 0.5 0.5 NA NA NA
Fluconazole 0.12 8 0.25 0.5 100 0 0
Voriconazole 0.008 0.12 0.008 0.008 100 0 0
Itraconazole 0.015 0.5 0.03 0.06 98.9 1.1 0
Posaconazole 0.008 2 0.015 0.03 NA NA NA
Micafungin 0.008 0.008 0.008 0.008 100 NA NA
Caspofungin 0.008 0.06 0.06 0.06 100 NA 0
Anidulafungin 0.015 0.12 0.06 0.12 100 NA NA
Flucytosine 0.06 0.5 0.06 0.12 100 NA NA
C. glabrata (45) Amphotericin B 0.12 1 0.5 1 NA NA NA
Fluconazole 4 > 256 16 32 28.9 66.7 4.4
Voriconazole 0.06 4 0.25 0.5 93.3 4.4 2.2
Itraconazole 0.25 > 16 1 1 0 44.4 55.6
Posaconazole 0.5 > 8 1 2 NA NA NA
Micafungin 0.008 2 0.008 0.008 100 NA NA
Caspofungin 0.06 > 8 0.12 0.12 97.8 NA 2.2
Anidulafungin 0.015 2 0.12 0.12 100 NA NA
Flucytosine 0.06 0.06 0.06 0.06 100 NA NA
C. tropicalis (43) Amphotericin B 0.25 1 0.5 1 NA NA NA
Fluconazole 0.25 > 256 2 64 88.4 0 11.6
Voriconazole 0.015 > 8 0.12 0.25 90.7 7 2.3
Itraconazole 0.06 > 16 0.25 0.5 27.9 69.8 2.3
Posaconazole 0.5 > 8 0.25 0.5 NA NA NA
Micafungin 0.008 0.06 0.015 0.015 100 NA NA
Caspofungin 0.03 0.25 0.06 0.12 100 NA 0
Anidulafungin 0.06 0.25 0.12 0.25 100 NA NA
Flucytosine 0.06 0.25 0.06 0.06 100 NA NA
C. parapsilosis (18) Amphotericin B 0.12 0.5 0.5 0.5 NA NA NA
Fluconazole 0.5 16 0.5 4 94.4 5.6 0
Voriconazole 0.008 0.12 0.008 0.12 100 0 0
Itraconazole 0.015 0.25 0.06 0.12 94.4 5.6 0
Posaconazole 0.015 0.25 0.03 0.12 NA NA NA
Micafungin 0.25 1 0.5 1 100 NA NA
Caspofungin 0.25 1 0.5 1 100 NA 0
Anidulafungin 0.5 2 1 2 100 NA NA
Flucytosine 0.06 0.5 0.12 0.275 100 NA NA
C. krusei (2) Amphotericin B 0.5 1 NA NA NA
Fluconazole 32 64 50
Voriconazole 0.25 0.25 0
Itraconazole 0.25 0.5 0
Posaconazole 0.25 0.25 NA NA NA
Micafungin 0.06 0.06 NA NA
Caspofungin 0.25 0.25 NA 0
Anidulafungin 0.12 0.12 NA NA
Flucytosine 16 16 NA NA
C. famata (2) Amphotericin B 0.5 8 NA NA NA
Fluconazole 2 > 256 50
Voriconazole 0.015 > 8 50
Itraconazole 0.25 > 16 50
Posaconazole 0.12 > 8 NA NA NA
Micafungin 0.06 0.06 NA NA
Caspofungin 0.25 0.25 NA 0
(continued on next page)
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Table 3 (continued)
Species (No. ) Antifungal agent Range
MIC (mg/mL) % (%) R or
Non-S50% 90% S SDD
Anidulafungin 0.12 0.25 NA NA
Flucytosine 0.06 0.06 NA NA
C. guilliermondii (2) Amphotericin B 0.25 0.5 NA NA NA
Fluconazole 4 8 0
Voriconazole 0.06 0.12 0
Itraconazole 0.5 0.5 0
Posaconazole 0.25 0.5 NA NA NA
Micafungin 0.05 > 8 NA NA
Caspofungin 0.25 > 8 NA 50
Anidulafungin 1 > 8 NA NA
Flucytosine 0.06 0.25 NA NA
I Z intermediate; NA Z not applicable; Non-SZ nonsusceptible; R Z resistant; S Z susceptible; SDDZ dose-dependent susceptible.
Breakpoint (mg/mL) for antifungal agents. Fluconazole: Susc:  8; SDD 16e32; R  64 Voriconazole: Susc:  1; SDD 2; R  4 Itraconazole:
Susc:  0.125; SDD 0.25e0.5; R  1 Posaconazole: Susc: None Micafungin: Susc:  2; NS: >2 Caspofungin: Susc:  2; NS: >2 Anidulafugin:
Susc:  2; NS: >2 Flucytosine: Susc:  4; I: 8e16; R  32.
312 I.-M. Hii et al.A major finding in the current study is the changing
distribution of Candida species among candidemia. In our
institute, although C. albicans is still the most common
pathogen, the proportion declined from 64.8% to 43.6%.
This is mainly due to the increase in cases of C. glabrata
candidemia from one (1.1%) during 2001e2003 to 47 (21.6%)
during 2009e2012 (p < 0.001). The proportions of other
non-C. albicans species, e.g., C. tropicalis and C. para-
psilosis, are also elevated slightly. The increasing trend
of non-C. albicans candidemia is consistent with other
studies.4,14e20 The reasons for the trend, however, are
less conclusive. Previous studies had identified that
when compared with C. albicans infections, fluconazole
use,21 antibiotic use,22e24 malignancy,22,24 abdominal sur-
gery,21,24 and age > 60 years24 were independent predictors
for C. glabrata infections. In addition to older age, we had
found that a higher proportion of female patients was
associated with C. glabrata candidemia. Some other
studies, such as Horn et al5 (n Z 274 of 525, 52.2%), Tapia
et al21 (n Z 37 of 68, 54.4%), Lee et al25 (n Z 77 of 144,
54%), and Malani et al26 (n Z 49 of 94, 52%), had shown a
higher proportion of female patients with C. glabrata can-
didemia. In another study,27 the authors found that C.
glabrata is the most isolated Candida species from theTable 4 Comparison of characteristics of patients with candide
Fluconazole reduced-susceptible stra
No (n Z 137) Yes (n Z 32)
Sex (male) 94 (68.6) 14 (43.8)
Broad-spectrum
antibiotic exposure
108 (78.8) 30 (93.8)
Fluconazole exposure
before candidemia
18 (13.1) 10 (31.3)vagina in female patients with type 2 diabetes, and the study
by Yang et al18 study revealed that urinary tract infection
was the most common source for C. glabrata candidemia
(71.9%). In the current study, we found that women had a
higher proportion of urinary tract infection as the primary
focus in comparison with men (12 of 24, 50% vs. 2/17, 11.8%,
pZ 0.018). We assumed that the anatomy and microbiota of
genitourinary tract of women led to the predominance of
C. glabrata candidemia in female patients.
In addition, environmental factors may have contributed
to the increasing trend of non-C. albicans candidemia. The
association of fluconazole use and increased incidence of
C. glabrata candidemia had been reported in several
studies.21,22,24 Although not significant, our current study
showed that higher proportions of patients with C. tropi-
calis or C. glabrata candidemia were exposed to flucona-
zole before the onset of candidemia (22.7% and 19.5%,
respectively). The interactions among host factors, envi-
ronment factors, and invading Candida species may be
complex and, as shown in our study, may evolve with time.
More meticulous studies are necessary to clarify these
interactions.
In the current study, the overall resistance rate of the






0.008 0.007 3.084 1.367e6.959
0.050 0.129 d d
0.013 0.010 3.403 1.334e8.682
Table 5 Factors associated with 30-day crude mortality during candidemia episodes
30-d mortality Univariate Multivariate
Survived (n Z 97) Died (n Z 112) p p OR 95% CI
APACHE score 16  7 22  9 < 0.001 < 0.001 1.134 1.084e1.188
Candidemia to antifungal therapy (d) (n Z 170) 0.87  3.949 (n Z 86) 0.08  3.915 (n Z 84) 0.193 d d d
Malignancy 39 (39.8) 59 (60.2) 0.072 0.010 2.496 1.240e5.024
Cirrhosis 4 (22.2) 14 (77.8) 0.031 0.005 7.598 1.858e31.066
CVC 74 (43.3) 97 (56.7) 0.054 d d d
Parenteral nutrition 24 (35.3) 44 (64.7) 0.025 0.001 3.515 1.664e7.427
Use of steroid 24 (34.3) 46 (65.7) 0.013 d d d
Neutropenia 5 (21.7) 18 (78.3) 0.012 0.034 4.203 1.115e15.842
Candida species 0.011 0.017 d d
C. albicans 39 (43.3) 51 (56.7) Reference
C. tropicalis 15 (34.1) 29 (65.9) 0.065 0.945 0.968 0.382e2.453
C. glabrata 24 (58.5) 17 (41.5) 0.082 0.040 0.389 0.158e0.958
C. parapsilosis 12 (80) 3 (20) 0.007 0.005 0.112 0.024e0.522
Othera 7 (36.8) 12 (63.2) 0.380 0.678 1.278 0.402e4.069
Candidemia by reduced-fuconazole susceptiblity strain 0.398 d d d
No 68 (49.6) 69 (50.4) Reference d d d
Yes 12 (37.5) 20 (62.5) 0.272 d d d
Otherb 17 (42.5) 23 (57.5) 0.581 d d d
a Including episodes with mixed candidemia or candidemia by Candida species other than C. albicans, C. tropicalis, C. glabrata, C. parapsilosis.
b Patients whose isolates were both susceptible and reduced-susceptible were not available or failed susceptibilty testing.



















314 I.-M. Hii et al.the C. albicans isolates were susceptible to fluconazole,
supporting the primary use of fluconazole in our institute.
There were several previous studies in Taiwan showing low
fluconazole resistance among all Candida fungemic iso-
lates, including 1.9% in the report by Yang et al,18 4.4% in
the study by Hsueh et al,19 0.04% in the study by Tsai et al,16
and 3.8% in the study by Chen et al.20 However, the
increasing trend of fluconazole resistant non-C. albicans
candidal infection had been cause for concern. As shown in
our study, 72.1% (30 of 45) of C. glabrata isolates and 11.6%
of C. tropicalis had reduced fluconazole susceptibility
(e.g., dose-dependent susceptible and resistant). The
resistance rate of C. glabrata in our study is compatible
with the finding in the study by Ruan et al,28 which showed
that the rate of fluconazole dose-dependent susceptibility
of C. glabrata isolates was higher (73%) in the later year
(2003 vs. 2007, pZ 0.003) but no resistance to fluconazole
among C. tropicalis isolates was detected in their study.
The resistance of C. tropicalis in our study is higher than
that in the study by Chen et al, which showed 5.9% (10 of
171) of fluconazole resistance in C. tropicalis from 1999 to
2006. However, the interpretation of differences of drug
resistance in Candida isolates among different studies and
study periods should be cautious because the drug resis-
tance may be affected by the methods used for suscepti-
bility testing. The study by Lombardi et al29 showed that
the agreement between National Committee for Clinical
Laboratory Standards (NCCLS) and Yeast One ranged from
95% (ketoconazole and itraconazole) to 100% (amphotericin
B and flucytosine), whereas the agreement between E-test
and YeastOne ranged from 72.5% (fluconazole) to 100%
(amphotericin B and flucytosine).
The risk factors for acquiring candidemia due to drug-
resistant strains had been studied. In a report by Tumbar-
ello et al,30 they found that patients with prior fluconazole
use, diabetes, and a central venous catheter were more
likely to develop fungemia due to a less susceptible isolate.
In our study, female sex and fluconazole exposure are the
only two independent risks for acquiring candidemia due to
fluconazole-resistant strains. The female sex as a risk factor
is likely due to the predominance of female patients with
C. glabrata candidemia in our study, which showed that
C. glabrata is the major Candida species with reduced
fluconazole susceptibility.
Several studies have described risk factors for mortality
of candidemia,16,26,31 including increasing age, greater
APACHE II score, use of immunosuppressive therapy, longer
duration of prior antibiotic use, retention of central venous
catheter, stay in ICU, malignancy, neutropenia, renal
insufficiency, and receipt of parenteral nutrition. We
identified that APACHE II score, malignancy, liver cirrhosis,
use of parenteral nutrition, neutropenia, and the invading
Candida species were independent risk factors for 30-day
crude mortality. In our study, patients with C. glabrata or
C. parapsilosis candidemia had favorable outcomes, with
30-day crude mortality of 41.5% for C. glabrata and 20% for
C. parapsilosis (odds ratio Z 0.389, p Z 0.040 and odds
ratio Z 0.112, p Z 0.005, respectively, when compared
with the mortality for C. albicans). Previous studies had
reported various mortality rates among different Candida
spp.20,22,31,32 The mortality rates range from 41.1% to 52%
for C. albicans, 41% to 58% for C. tropicalis, 31% to 60% forC. glabrata, and 22.9% to 26% for C. parapsilosis. The
variation of mortality rates in different studies may be
owing to heterogeneous underlying conditions that influ-
ence the prognosis of patients.
Some reported treatment failures associated with in-
fections of fluconazole resistant candidal strains. The study
by Chen et al33 showed that candidemia attributable
mortality was correlated with reduced fluconazole sus-
ceptibility. However, as in the report by Lee et al,25 we also
failed to demonstrate the association between drug sus-
ceptibility of Candida species and clinical outcome. The
30-day mortality rate of patients infected with reduced
fluconazole susceptible strains was similar to that of pa-
tients infected with fluconazole-susceptible strains (50.4%
vs. 62.5%; p Z 0.272). Prompt antifungal therapy might
influence the outcome as noted in the study by Chen et al.14
However, the difference of time from onset of candidemia
to effective antifungal therapy between surviving and fatal
cases was not significant in our study. More studies with
large sample size and adjusting all the factors influencing
mortality are necessary to make a conclusion about the
effects of drug susceptibility of Candida species and timely
and adequate use of antifungal agents on the outcome of
patients.
The major limitation of this study is its retrospective
design with high heterogenicity in characteristics among
patients and small sample sizes when attempting subgroup
analysis. However, our findings still offer valuable points in
the management of patients with candidemia. In conclu-
sion, the results of this study showed that although C.
albicans remained the most isolated species, the propor-
tion of non-C. albicans candidemia, especially C. glabrata,
was increasing. The drug resistance of clinical candidal
isolates to the primary agents, e.g., fluconazole and echi-
nocandins, remained low but candidemias due to reduced
fluconazole susceptibility non-C. albicans Candida species,
especially C. glabrata, were increasing. The prognosis of
patients with candidemia was still poor. Further studies are
necessary with focus on prompt identification of patients at
risk for candidemia due to resistant strains and the effect
of appropriate antifungal therapy on mortality.References
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